Intellia Therapeutics
(NASDAQ) NTLA
Intellia Therapeutics Financials at a Glance
Market Cap
$1.52B
Revenue (TTM)
$67.67M
Net Income (TTM)
$412.69M
EPS (TTM)
$-3.83
P/E Ratio
-3.36
Dividend
$0.00
Beta (Volatility)
1.92 (High)
Dividend
$0.00
Beta (Volatility)
1.92 (High)
Price
$12.84
Volume
104,826
Open
$13.13
Price
$12.84
Volume
104,826
Open
$13.13
Previous Close
$12.84
Daily Range
$12.81 - $13.57
52-Week Range
$5.90 - $28.25
Dividend
$0.00
Beta (Volatility)
1.92 (High)
Price
$12.84
Volume
104,826
Open
$13.13
Previous Close
$12.84
Daily Range
$12.81 - $13.57
52-Week Range
$5.90 - $28.25
NTLA News
NTLA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Intellia Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
377
CEO
John M. Leonard, MD
Website
www.intelliatx.comHeadquarters
Cambridge, MA 02139, US
NTLA Financials
Key Financial Metrics (TTM)
Gross Margin
-26%
Operating Margin
-7%
Net Income Margin
-6%
Return on Equity
-53%
Return on Capital
-60%
Return on Assets
-49%
Earnings Yield
-29.76%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.52B
Shares Outstanding
118.13M
Volume
104.83K
Short Interest
0.00%
Avg. Volume
4.73M
Financials (TTM)
Gross Profit
$51.75M
Operating Income
$440.99M
EBITDA
$396.77M
Operating Cash Flow
$348.88M
Capital Expenditure
$5.78M
Free Cash Flow
$354.66M
Cash & ST Invst.
$449.88M
Total Debt
$93.33M
Intellia Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$23.02M
+78.8%
Gross Profit
$17.00M
+32.1%
Gross Margin
73.87%
N/A
Market Cap
$1.52B
N/A
Market Cap/Employee
$3.76M
N/A
Employees
403
N/A
Net Income
$95.79M
+25.7%
EBITDA
$95.41M
+28.7%
Quarterly Fundamentals
Net Cash
$356.56M
-8.9%
Accounts Receivable
$9.47M
+11.2%
Inventory
$0.00
N/A
Long Term Debt
$66.85M
-64.8%
Short Term Debt
$26.48M
+30.8%
Return on Assets
-49.01%
N/A
Return on Invested Capital
-59.74%
N/A
Free Cash Flow
$69.41M
+19.5%
Operating Cash Flow
$69.28M
+18.7%